Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H30N2O2 |
| Molecular Weight | 414.5393 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)CCC(C)(C)C2=C1C=C(CN3C=CC=N3)C(\C=C\C4=CC=C(C=C4)C(O)=O)=C2
InChI
InChIKey=YTFHCXIPDIHOIA-DHZHZOJOSA-N
InChI=1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)/b11-8+
Palovarotene (R-667, RO-3300074) was developed by Roche Holding AG as a selective retinoic acid receptor gamma agonist for the treatment of emphysema. Phase I clinical trials of palovarotene in patients with emphysema demonstrated that the drug is well tolerated, with improvements observed in markers of emphysema progression. Unlike all-trans retinoic acid, the pharmacokinetic profile of palovarotene appears to be dose-proportional. However, those studies were discontinued. Palovarotene is also being investigated in phase II of the clinical trial in the treatment of Fibrodysplasia Ossificans Progressiva (FOP). Palovarotene received Fast Track designation from the U.S. Food and Drug Administration (FDA) and orphan designations for the treatment of FOP from both the FDA and the European Medicines Agency (EMA).
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2003 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19876792 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17324249 |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PALOVAROTENE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
57.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17324249 |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PALOVAROTENE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. | 2011-04 |
|
| Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments. | 2010-12 |
|
| Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema. | 2009-11 |
|
| Treatment of patients who have fibrodysplasia ossificans progressiva with isotretinoin. | 1998-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22282548
double-blind, placebo-controlled randomised study to assess the safety and efficacy of 5 mg·day(-1) palovarotene given for 1 year to 262 patients with severe α(1)-antitrypsin deficiency and emphysema confirmed by computed tomography.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C804
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
||
|
FDA ORPHAN DRUG |
438714
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
||
|
FDA ORPHAN DRUG |
612117
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/14/1368
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
28K6I5M16G
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
28K6I5M16G
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
100000137437
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
SUB75998
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
410528-02-8
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
DTXSID301025696
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
C546535
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
9025
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
10295295
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
UU-92
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
C80661
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105648
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
DB12320
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
Palovarotene
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY |
ACTIVE MOIETY